Peripheral T cell lymphoma: clinical utility of romidepsin
Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-06-01
|
Series: | Blood and Lymphatic Cancer : Targets and Therapy |
Online Access: | http://www.dovepress.com/peripheral-t-cell-lymphoma-clinical-utility-of-romidepsin-a10099 |